Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. (SHE:300452)
China · Delayed Price · Currency is CNY 12.89
-0.18 (-1.38%)
Sep 10, 2026, 3:04 PM CST
SHE:300452 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 3,040 | 3,113 | 2,817 | 3,308 | 4,071 | 3,916 | |
Market Cap Growth | -4.80% | 10.49% | -14.85% | -18.74% | 3.96% | 26.59% |
Enterprise Value | 2,596 | 2,766 | 2,573 | 3,058 | 3,852 | 3,747 |
Last Close Price | 13.07 | 13.05 | 11.52 | 13.28 | 16.11 | 15.23 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 17.66 | 17.63 | 23.59 | 20.48 | 31.15 | 43.88 |
Forward PE | 15.94 | 15.93 | 14.16 | 19.57 | 62.00 | 62.00 |
PS Ratio | 3.06 | 3.30 | 3.19 | 3.94 | 5.78 | 6.35 |
PB Ratio | 2.76 | 2.90 | 2.89 | 3.54 | 5.16 | 5.55 |
P/TBV Ratio | 3.10 | 3.27 | 3.30 | 4.27 | 6.47 | 7.17 |
P/FCF Ratio | 19.24 | 20.58 | 31.17 | 42.76 | 62.16 | 54.13 |
P/OCF Ratio | 15.00 | 16.21 | 23.81 | 25.01 | 30.65 | 37.72 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.61 | 2.93 | 2.92 | 3.64 | 5.47 | 6.08 |
EV/EBITDA Ratio | 10.30 | 11.31 | 11.63 | 15.28 | 24.52 | 29.33 |
EV/EBIT Ratio | 13.11 | 14.47 | 15.10 | 18.96 | 31.83 | 40.26 |
EV/FCF Ratio | 16.43 | 18.29 | 28.46 | 39.53 | 58.80 | 51.79 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.31 | 0.29 | 0.31 | 0.32 | 0.05 | 0.04 |
Debt / EBITDA Ratio | 1.37 | 1.29 | 1.38 | 1.49 | 0.25 | 0.24 |
Debt / FCF Ratio | 2.19 | 2.08 | 3.37 | 3.85 | 0.61 | 0.43 |
Net Debt / Equity Ratio | -0.46 | -0.47 | -0.41 | -0.41 | -0.41 | -0.42 |
Net Debt / EBITDA Ratio | -2.04 | -2.07 | -1.82 | -1.94 | -2.07 | -2.33 |
Net Debt / FCF Ratio | -3.24 | -3.35 | -4.46 | -5.02 | -4.96 | -4.12 |
Asset Turnover | 0.59 | 0.58 | 0.57 | 0.62 | 0.66 | 0.66 |
Inventory Turnover | 6.89 | 7.12 | 6.67 | 6.20 | 5.86 | 6.93 |
Quick Ratio | 3.44 | 3.75 | 3.92 | 3.04 | 1.42 | 2.06 |
Current Ratio | 3.82 | 4.14 | 4.38 | 3.44 | 1.83 | 2.48 |
Return on Equity (ROE) | 16.89% | 16.90% | 12.62% | 19.10% | 17.52% | 12.57% |
Return on Assets (ROA) | 7.31% | 7.30% | 6.87% | 7.41% | 7.06% | 6.24% |
Return on Invested Capital (ROIC) | 28.27% | 29.25% | 25.79% | 28.28% | 26.65% | 20.52% |
Return on Capital Employed (ROCE) | 13.50% | 13.30% | 12.90% | 12.70% | 14.50% | 12.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | 5.91% | 5.67% | 4.24% | 4.88% | 3.21% | 2.28% |
FCF Yield | 5.20% | 4.86% | 3.21% | 2.34% | 1.61% | 1.85% |
Dividend Yield | 2.34% | 2.30% | 2.60% | 1.88% | 1.55% | 1.52% |
Payout Ratio | 40.64% | 40.46% | 49.41% | 37.01% | 42.33% | 51.90% |
Buyback Yield / Dilution | -2.36% | -3.28% | 2.88% | -3.29% | 0.63% | -1.93% |
Total Shareholder Return | -0.02% | -0.98% | 5.48% | -1.41% | 2.18% | -0.42% |